Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Paroxetine and Study 329: what we already knew and when.

Sasich LD.

BMJ. 2015 Oct 14;351:h5411. doi: 10.1136/bmj.h5411. No abstract available.

PMID:
26468042
2.

Clinical trial transparency.

Sasich LD.

CMAJ. 2015 Oct 6;187(14):1077. doi: 10.1503/cmaj.1150063. No abstract available.

3.

Pharmaceutical policies used by private health insurance companies in Saudi Arabia.

Bawazir SA, Alkudsi MA, Al Humaidan AS, Al Jaser MA, Sasich LD.

Saudi Pharm J. 2013 Jul;21(3):267-76. doi: 10.1016/j.jsps.2012.10.005. Epub 2012 Nov 12.

4.

The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab).

Sasich LD, Sukkari SR.

Saudi Pharm J. 2012 Oct;20(4):381-5. doi: 10.1016/j.jsps.2011.12.001. Epub 2011 Dec 28.

5.

The usefulness and scientific accuracy of private sector Arabic language patient drug information leaflets.

Sukkari SR, Al Humaidan AS, Sasich LD.

Saudi Pharm J. 2012 Jul;20(3):211-5. doi: 10.1016/j.jsps.2012.01.006. Epub 2012 Jan 28.

6.

Drug approval packages and briefing documents are already freely available.

Sasich LD, Abi-Jaoude E.

BMJ. 2013 Aug 13;347:f4861. doi: 10.1136/bmj.f4861. No abstract available.

PMID:
23943743
7.

Analysis of metformin treatment for adolescent obesity at 48 rather than 24 weeks after treatment cessation.

Sukkari SR, Sasich LD, Humaidan AS, Burikan O.

Arch Pediatr Adolesc Med. 2010 Jul;164(7):678; author reply 678-9. doi: 10.1001/archpediatrics.2010.110. No abstract available.

PMID:
20603472
8.

An academic perspective on the APPEs' educational significance.

Sukkari SR, Sasich LD, Barasain MA.

Am J Pharm Educ. 2009 Dec 17;73(8):139. No abstract available.

9.

FDA drug information that never reaches clinicians.

Cook GE, Sasich LD, Sukkari SR.

N Engl J Med. 2010 Feb 11;362(6):562-3; author reply 563. No abstract available.

PMID:
20175263
10.

Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone.

Cook GE, Sasich LD, Sukkari SR.

BMJ. 2010 Jan 19;340:c285. doi: 10.1136/bmj.c285. No abstract available.

PMID:
20085974
11.

The importance of FDA approval packages and briefing documents in pharmacy education.

Sasich LD, Sukkari SR, Cook GE, Tuttle DA.

Am J Pharm Educ. 2009 Nov 12;73(7):126. No abstract available.

12.

Improving access to FDA reviews and documents.

Tuttle DA, Sasich LD, Sukkari SR.

JAMA. 2009 Nov 25;302(20):2204; author reply 2205. doi: 10.1001/jama.2009.1726. No abstract available.

PMID:
19934420
13.

Look in the looking glass, not through it.

Sukkari SR, Sasich LD.

Am J Pharm Educ. 2009 May 27;73(3):56. No abstract available.

14.

Development and evaluation of a required patient safety course.

Sukkari SR, Sasich LD, Tuttle DA, Abu-Baker AM, Howell H.

Am J Pharm Educ. 2008 Jun 15;72(3):65.

15.

The cardiovascular risks of etoricoxib (Arcoxia).

Sasich LD, Barasain MA, Al Kudsi MA.

Ann Saudi Med. 2008 Mar-Apr;28(2):141-2. No abstract available.

16.

Unknown risks of pharmacy-compounded drugs.

Sasich LD, Sukkari SR.

J Am Osteopath Assoc. 2008 Feb;108(2):86. No abstract available.

PMID:
18303067
17.

Accessing FDA approval packages and briefing documents.

Ohmer J, Miller JW, Sasich LD.

Ann Pharmacother. 2007 Dec;41(12):2071-2. Epub 2007 Oct 30. No abstract available.

PMID:
17971408
18.

Remembering Jere Goyan.

Sasich LD.

Am J Health Syst Pharm. 2007 Jun 1;64(11):1142. No abstract available.

PMID:
17519452
19.

Incomplete patient drug information still a problem.

Sukkari SR, Sasich LD.

CMAJ. 2004 Nov 9;171(10):1149-50; author reply 1150. No abstract available.

20.

Cisapride and patient information leaflets.

Sukkari SR, Sasich LD.

CMAJ. 2001 May 1;164(9):1276-8; author reply 1278-9. No abstract available.

21.

Information on thiazolidinediones.

Wolfe SM, Lurie P, Sasich LD, Barbehenn E.

Lancet. 2000 Jul 15;356(9225):254-5. No abstract available.

PMID:
10963229
22.

Safety of FDA-approved drugs.

Lurie P, Sasich LD.

JAMA. 1999 Dec 22-29;282(24):2297-8. No abstract available.

PMID:
10612311
23.

Useful prescription drug information.

Sasich LD.

Am J Health Syst Pharm. 1999 Mar 1;56(5):477-9. No abstract available.

PMID:
10096713
24.

Trials of CCBs.

Sukkari SR, Sasich LD.

CMAJ. 1998 Jan 13;158(1):21-3. No abstract available.

25.

The National Council on Patient Information and Education.

Sasich LD, Wolfe SM, Pearson C, Swankin DA, Levin AA, Beard J.

JAMA. 1997 Nov 12;278(18):1491-2. No abstract available.

PMID:
9363963
26.

Expanding clinical services.

Sasich LD.

Am Pharm. 1988 Jun;NS28(6):5. No abstract available.

PMID:
3247888
27.

A proposal for a community pharmacy practice residency program.

Sasich LD.

Am Pharm. 1983 May;NS23(5):25-8. No abstract available.

PMID:
6881053

Supplemental Content

Loading ...
Support Center